Quantcast

Latest Ataxia Stories

2010-12-14 00:45:53

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means.

2010-08-02 07:49:00

WALTHAM, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases.

2010-07-22 10:07:00

DEARBORN, Mich., July 22 /PRNewswire/ -- Accelerated research findings leading to potentially significant new treatments for fragile X syndrome (FXS) will be presented to nearly 1,000 family members and professionals at the 12th International Fragile X Conference in Dearborn July 21-25.

2010-06-09 06:00:00

WALTHAM, Mass., June 9 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010.

2010-05-24 09:04:00

WALTHAM, Mass., May 24 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich's ataxia.

2010-05-13 06:00:00

WALTHAM, Mass., May 13 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor.

2010-03-18 09:45:00

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease. The Barteks are co-founders of the Friedreich's Ataxia Research Alliance, an organization dedicated to the pursuit of scientific research leading to treatments and a cure for the disease.

2010-02-04 07:00:00

WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the third quarter of fiscal year 2010, ended December 31, 2009.

2009-12-15 08:00:00

WALTHAM, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).

2009-11-20 20:30:00

Pioneering Neurologist Closer to Understanding Brain Wiring and Diseases WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Dr.


Word of the Day
friseur
  • A hairdresser.
The word 'friseur' comes from French friseur, from friser ("to curl, frizz").
Related